rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment

Vaccine: X
Thomas P MonathBrighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG)

Abstract

The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) was formed to evaluate the safety and characteristics of live, recombinant viral vector vaccines. A recent publication by the V3SWG described live, attenuated, recombinant vesicular stomatitis virus (rVSV) as a chimeric virus vaccine for HIV-1 (Clarke et al., 2016). The rVSV vector system is being explored as a platform for development of multiple vaccines. This paper reviews the molecular and biological features of the rVSV vector system, followed by a template with details on the safety and characteristics of a rVSV vaccine against Zaire ebolavirus (ZEBOV). The rVSV-ZEBOV vaccine is a live, replication competent vector in which the VSV glycoprotein (G) gene is replaced with the glycoprotein (GP) gene of ZEBOV. Multiple copies of GP are expressed and assembled into the viral envelope responsible for inducing protective immunity. The vaccine (designated V920) was originally constructed by the National Microbiology Laboratory, Public Health Agency of Canada, further developed by NewLink Genetics Corp. and Merck & Co., and is now in final stages of registration by Merck. The vaccine is attenuated by deletion of the principal virulence factor of VSV (the...Continue Reading

References

Nov 1, 1976·The Journal of General Virology·J J HollandE Scolnick
Sep 1, 1988·The American Journal of Tropical Medicine and Hygiene·E QuirozR B Tesh
Jan 1, 1987·The American Journal of Tropical Medicine and Hygiene·J S ReifG Cholas
Mar 1, 1966·The American Journal of Tropical Medicine and Hygiene·K M JohnsonP H Peralta
Sep 1, 1967·American Journal of Epidemiology·A H Jonkers
Nov 9, 1967·The New England Journal of Medicine·B N Fields, K Hawkins
Apr 15, 1982·Journal of Molecular Biology·K S MatlinK Simons
Dec 1, 1982·The Journal of General Virology·P N FultzJ W Streilein
May 1, 1983·The American Journal of Tropical Medicine and Hygiene·R B Tesh, G B Modi
Dec 1, 1995·Immunological Reviews·M F van den BroekM Aguet
Apr 1, 1997·Journal of Veterinary Diagnostic Investigation : Official Publication of the American Association of Veterinary Laboratory Diagnosticians, Inc·E W HowerthG R Clarke
Apr 10, 1999·Journal of Virology·A RobertsJ K Rose
May 18, 1999·The Veterinary Journal·G J LetchworthJ Del cbarrera
Jun 19, 2003·Pharmacoepidemiology and Drug Safety·Katrin S KohlElisabeth Loupi
Feb 1, 1957·American Journal of Public Health and the Nation's Health·C A BRANDLY, R P HANSON
Sep 29, 2004·Journal of Virology·David A Coil, A Dusty Miller
Jan 27, 2005·Viral Immunology·Glen N Barber
Dec 8, 2006·Journal of Virology·Damian L TurnerLeo Lefrançois
Jul 17, 2007·Clinical Microbiology Reviews·Els N T MeeusenGregers Jungersen
Dec 6, 2007·The Journal of Infectious Diseases·Steven M JonesHeinz Feldmann
Nov 26, 2008·Nature Immunology·Troy D QuerecBali Pulendran
Jul 27, 2010·Reviews in Medical Virology·Thomas W GeisbertHeinz Feldmann
Aug 26, 2011·Nature·Jan E CaretteThijn R Brummelkamp
Sep 20, 2011·Viruses·Judith OlejnikElke Mühlberger
Oct 19, 2011·The Journal of Infectious Diseases·Andrea MarziHeinz Feldmann
Oct 19, 2011·The Journal of Infectious Diseases·Thomas W Geisbert, Heinz Feldmann

❮ Previous
Next ❯

Citations

Aug 25, 2020·Current Protocols in Microbiology·Alaa A Abdelmageed, Maureen C Ferran
Aug 2, 2019·Human Vaccines & Immunotherapeutics·Anahita FathiMarylyn M Addo
Jul 13, 2020·Vaccine·Sonali KochharUNKNOWN Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG)
Jul 1, 2020·Advanced Drug Delivery Reviews·Darrell J IrvineMurillo Silva
Mar 21, 2020·MethodsX·Jean-François GélinasAmine A Kamen
Sep 11, 2020·Vaccine·Richard C ConditUNKNOWN Brighton Collaboration Benefit-Risk Assessment of Vaccines by Technology (BRAVATO) Working Group. Electronic address: bc-coo
Dec 7, 2019·Journal of Autoimmunity·Manuel RojasJuan-Manuel Anaya
Dec 18, 2020·Nature Communications·Yfat Yahalom-RonenTomer Israely
Feb 24, 2021·NPJ Vaccines·Nikolaos C KyriakidisEsteban Ortiz Prado
Mar 8, 2021·Vaccine·Jerome CustersUNKNOWN Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG)
Mar 7, 2021·Vaccines·Jayanthi WolfJakub K Simon
Apr 3, 2021·Scientific Reports·Geoffri RicciMalini Mukherjee
Apr 11, 2021·Biotechnology and Bioengineering·Sascha KiesslichAmine A Kamen
May 21, 2021·BMJ Global Health·Patrick L F ZuberMartin H Friede
Jun 11, 2021·Biotechnology and Bioengineering·Osnat RosenEyal Epstein

❮ Previous
Next ❯

Methods Mentioned

BETA
transfection
ELISA
PCR

Related Concepts

Related Feeds

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.